Recent 8-K filings for HRGN

• April 28, 2026, 7:59 PM ET other material materiality 0.70 positive item 7.01item 9.01

  Harvard Apparatus Regenerative Technology treats first patient in Phase 1 esophageal implant trial

  First patient treated with Cellspan Esophageal Implant (CEI) in Phase 1 clinical trial at Mayo Clinic.

• April 15, 2026, 7:59 PM ET debt materiality 0.60 neutral item 1.02item 9.01

  Harvard Apparatus receives $300K bridge loan from CEO Junli He at 8% interest

  Loan of $300,000 from Chairman/CEO Junli He; annual 8% fixed interest rate.

• July 14, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 9.01

  Harvard Apparatus raises $2.0M via private placement of 1.25M shares at $1.60/share

  Sold 1,250,000 shares of common stock to accredited investors for aggregate proceeds of ~$2.0M.

• June 24, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.07

  Harvard Apparatus shareholders approve reverse stock split and declassification amendment at annual meeting

  Reverse stock split amendment approved; Board authorized to determine ratio and timing at discretion.

• November 6, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 9.01

  Harvard Apparatus Regenerative Technology signs exclusive global distribution deal with Health Regen through 2030

  Exclusive distribution of consumer health/dietary supplements from Nov 1, 2024 to Dec 31, 2030; auto-renews for 6 years if targets met.

• April 17, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements

  Harvard Apparatus Regenerative Technology raises $1.5M in private placement of 367,767 shares at $4.03/share

  Aggregate purchase price of $1.5 million for 367,767 shares at $4.03 per share in a private placement.

Executive changes

Materiality & sentiment trend

Max materiality 0.75 · Median 0.60 · Most common event other_material

1 positive 0 negative 10 neutral

source · HRGN on sec.gov